6661
威健生技
-0.54%
(-0.01)
威健生技 (6661.TW) 2025Q3 financial report shows net profit of 7M TWD, with a YoY growth rate of -8.63%, slightly lower than the same period last year, indicating profitability is starting to weaken and operational pressure is increasing. It is recommended to keep tracking revenue, cash flow, and expense structure, and use Growin AI Value Analysis to observe whether the company can adjust its operating strategy. If the core business remains stable, short-term challenges are still manageable.